PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.

Jones D, Woyach JA, Zhao W, Caruthers S, Tu H, Coleman J, Byrd JC, Johnson AJ, Lozanski G
Leukemia 31 1645-1647 01/01/2017

Abstract

Full Text